Expression of survivin, caspase-3 and p53 in cervical cancer assessed by tissue microarray: correlation with clinicopathology and prognosis.

OBJECTIVE

The aim of this study was to determine the role of survivin, caspase-3 and p53 expression in cervical cancer, and their correlation with clinicopathological features and prognosis.

METHODS

Two hundred and twenty-eight cases of cervical disease were analyzed retrospectively between February 2003 and May 2007 at Taizhou Hospital of Taizhou Enze Medical Center. The expressions of survivin, caspase-3 and p53 were detected by immunohistochemistry (EnVision), assessed by tissue microarray. The correlation of the three genes and clinicopathological factors as well as prognosis were statistically analyzed.

RESULTS

The results showed that the positive expression rate of survivin, caspase-3 and p53 in cervical cancer was significantly higher than in the CIN group and cervicitis group (p < 0.05). The expression of survivin was related with clinical staging, stromal involvement and lymph node metastasis (p < 0.05). The positive ratio of caspase-3 was significantly different from histological grading (p < 0.05). The positive expression of p53 was correlated with histological type and grading (p < 0.05). The expression of survivin in cervical cancer was negatively associated with that of caspase-3 (p < 0.01). The positive expression of survivin in the survival group and non-survival group was significantly statistically difference (p < 0.01). There was a significant difference between survivin expression and survival duration by the log-rank method. Whereas no association with survival was seen for caspase-3 and p53 positivity.

CONCLUSION

Survivin, caspase-3 and p53 may play an important role in the occurrence and development of cervix carcinoma. It has been suggested that the high expression of survivin or p53 and low expression of caspase-3 are closely correlated with cervical cancer. They could be used as markers for malignant degree and invasiveness of cervix cancer. Survivin can also be used in the estimation of prognosis and survival time of cervix carcinoma.